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Background
Schizophrenia is a disorder which lasts for a person's
lifetime. Treating it is a formidable challenge for clinician's
considering the chronic nature of its course, rate of relapse,
side effects of medicines and limited choice of medications.
Since 1950s, with the advent of Chlorpromazine  efforts have
been made to alleviate the symptoms of schizophrenia and
make them useful in terms of social and occupational
functioning. Expected success of Antipsychotic (AP)
medications depends on the results of the efficacy and
effectiveness trials.1
Numerous studies have been done to evaluate the
efficacy of conventional and atypical antipsychotic.2-5 There
are many issues with these studies: some had limited sample
size, mostly comparing antipsychotics with placebo and
others were sponsored by pharmaceutical industry. In a study
analyzing the role of pharmaceutical industry in influencing
results, Heres et al concluded that in around 92% of studies
results were skewed towards funding industry.6 This could be
due to the fact that the Industry spends huge sum of money in
developing a compound through tedious process of research
and only clinically viable compounds see the light of Phase II
and III research. Another issue is the usefulness of the
efficacy trial in real world clinical situation where situation is
much different; patients often have co-morbid condition,
chronic nature of the condition and explicit preferences for
therapy dictates decision making. 
Catie - Study Design and Results:
Clinical Antipsychotics Trial of Intervention
Effectiveness (CATIE) is the double-blind randomized-
control trial, conducted in naturalistic settings across fifty
seven geographical and variable clinical setting sites of
United States of America (USA).7 The study was
conducted on 1493 patients, from October 2001 to
December 2004. The idea behind such a trial was to have
high internal and external validity. The trial was funded by
National Institute of Mental Health. The aim was to asses
and compare effectiveness of first generation and second
generation (atypical) antipsychotics. The study also looked
into side effects of medications. It also intends to measure
the efficacy of Clozapine over other atypical APs. Study
was conducted in three phases. Primary out-come measure
was "time to discontinue", for any cause; lack of
tolerability; lack of efficacy; clinical decision and patient
decision. Secondary outcome measure was assessed by
scores on Positive and Negative syndrome scale (PANS)
and scores on Clinical global impression scale (CGI).
Higher scores point towards more severe psychopathology
and severity of illness respectively. Safety was also
measured at intervals to see any neurological, metabolic
and laboratory derangement. For estimation of primary out-
come measure, authors used Kaplan-Meier curve. Cox
proportional-hazards regression model was used to
compare treatment groups.
PHASE 01:A total of 1493 patients were assigned to
double blind treatment with olanzapine (7.5 mg to 30 mg per
day), perphenazine (8 to 32 mg per day), quetiapine (200 to
800 mg per day), ziprasidone (40 to 160 mg per day) or
risperidone (1.5 to 6 mg per day) for up to 18 months. People
with Tardive dyskinesia were excluded to receive
perphenazine. These patients were not with the first episode
of psychosis. Data from one center (n=33) was excluded due
to data integrity issues. Out of 1460 individuals who were
randomized initially, 371 completed the phase 1 trial (1089
discontinued). 
PHASE 02: In the stage 543 patients entered in to two
pathways; "efficacy" pathway with clozapine (n=99) or
"tolerability" (n=444) pathway with ziprasidone. A total of
509 patients left the study before the start of this phase. 
PHASE 03: This was an open-label phase of the
study. Patients were free to select one among 09 AP regimens;
270 patients entered in this phase of the trial. 
Results of this study were published in different
journals as they came up.7-9 The most prominent finding was
all-cause discontinuation rate of 74% at 18 months. In terms
of discontinuation of medication due to any cause before the
completion of the study, Olanzapine fared better then
Quetiapine (hazard ratio, 0.63; P<0.001) Risperidone (hazard
ratio, 0.75: P=0.0002) and also with other medications. The
discontinuation due to intolerable side effects was similar
among all the groups, with more individuals discontinuing
Olanzapine due to weight gain (07 percent or more of the
baseline body weight) and increase in glycosylated
haemoglobin, cholesterol and triglyceride leading to
metabolic syndrome. In case of perphenazine Extrapyramidal
symptoms were the most common reason for discontinuation
(08 percent vs. 02 percent to 04 percent, P=0.002).
Research team was unable to find any superior
efficacy of Atypical over conventional AP, i.e. Perphenazine.
Perphenazine was however most cost-effective when
compared with newer atypical APs. Clozapine was the most
effective compound compared with all the other
antipsychotics used in this study. Irrespective of the class of
antipsychotics, there was improvement in neuro-cognitive
functioning. However this effect remained significant only
for two months. Among all, Ziprasiodne was most weight
neutral and did not come up with any metabolic side-effects.
In the last phase which was open label, very few patients
selected conventional antipsychotics (Fluphenazine
decanoate, n=09 or Perphenazine, n=04)
Critique: 
One of the main critiques of this study is that
researchers have used drug doses which are on the higher side
compared to actual clinical practice.  This could have caused
a difference in the results. Another objection was that
although the total period of study was 18 months, much more
than previous studies, it was still short considering the long
course of schizophrenia, delays in response and side-effects
of medications. . Open label component of the trial could
have also caused a possible bias.10
CATIE results are important in view of the
prevailing health care situation in Pakistan; health is an out
of pocket expenditure for most Pakistanis. Government's
contribution is dismally low, i.e. US $ 04 out of US $ 18 per
capita. Considering the Global economic recession,
affordable health care is becoming a challenge for most
patients and their family members. Given the lack of
difference between the efficacy of conventional and atypical
APs, an affordable care becomes a reality to the vast
majority of patients with schizophrenia in a developing
country like Pakistan. Given the extra pyramidal side effects
(EPSE) with conventional APs and Metabolic syndrome
with atypical APs clinicians are advised caution in terms of
drug prescription. Every patient who is on AP should be
reviewed periodically for dose-adjustment in order to
achieve symptoms remission, review drug side effects and
enhance compliance. 
In conclusion the best practice evidence on treatment
of schizophrenia remain open to interpretation given the
trade-offs between efficacy, side effects, affordability and
implicit personal preferences. The perennial question, that do
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we know enough, still remains unanswered. 
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